Carcinoma-associated elF3i overexpression facilities mTOR-dependent growth transformation

Molecular Carcinogenesis

Volumn 45, Issue 12, 2006, Pages 957-967

  Ahlemann, Martin ^a   Zeidler, Reinhard ^b   Lang, Stephan ^a   Mack, Brigitte ^b   Münz, Markus ^b,c   Gires, Olivier ^b,c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

AMIDA; elF3i; mRNA translation; mTOR; PI3K; Rapamycin

Indexed keywords

INITIATION FACTOR; INITIATION FACTOR 3; INITIATION FACTOR 3I; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOTRANSFERASE; RAPAMYCIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; REGULATORY SUBUNIT RIIALPHA, CYCLIC AMP DEPENDENT PROTEIN KINASE; REGULATORY SUBUNIT RIIALPHA, CYCLIC-AMP-DEPENDENT PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CARCINOMA; CELL ANCHORAGE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SIZE; CELL STIMULATION; CONTROLLED STUDY; ENZYME INHIBITION; FUNCTIONAL PROTEOMICS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS REGULATION; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TRANSLATION REGULATION; TUMOR GROWTH; AMINO ACID SEQUENCE; ANIMAL; CELL CYCLE; CELL MEMBRANE; CHEMISTRY; GENE DELETION; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHOSPHORYLATION; TRANSACTIVATION; TUMOR CELL LINE;

EUKARYOTA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SEQUENCE; ANIMALS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SIZE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EUKARYOTIC INITIATION FACTOR-3; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; RNA, MESSENGER; SEQUENCE DELETION; TRANS-ACTIVATION (GENETICS); TRANSFORMING GROWTH FACTOR BETA;

EID: 33845397658     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20269     Document Type: Article

References (30)

1. Dever TE. Gene-specific regulation by general translation factors. Cell 2002;108:545-556.
2. Nilsson J, Sengupta J, Frank J, Nissen P. Regulation of eukaryotic translation by the RACK1 protein: A platform for signalling molecules on the ribosome. EMBO Rep 2004;5:1137-1141.
3. Gebauer F, Hentze MW. Molecular mechanisms of translational control. Nat Rev Mol Cell Biol 2004;5:827-835.
4. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005;123:569-580.
5. Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151-3171.
6. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24:200-216.
7. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005;17:158-166.
8. Mayeur GL, Fraser CS, Peiretti F, Block KL, Hershey JW. Characterization of elF3k: A newly discovered subunit of mammalian translation initiation factor elF3. Eur J Biochem 2003;270:4133-4139.
9. Asano K, Kinzy TG, Merrick WC, Hershey JW. Conservation and diversity of eukaryotic translation initiation factor elF3. J Biol Chem 1997;272:1101-1109.
10. Rauch J, Ahlemann M, Schaffrik M, et al. Allogenic antibody-mediated identification of head and neck cancer antigens. Biochem Biophys Res Commun 2004;323:156-162.
11. Huang JS, Chao CC, Su TL, et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular-carcinoma. Biochem Biophys Res Commun 2004;315:950-958.
12. Mitchison JM. Growth during the cell cycle. Int Rev Cytol 2003;226:165-258.
13. Mitchison JM, Novak B, Sveiczer A. Size control in the cell cycle. Cell Biol Int 1997;21:461-463.
14. Neufeld TP, Edgar BA. Connections between growth and the cell cycle. Curr Opin Cell Biol 1998;10:784-790.
15. Martin KA, Blenis J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 2002;86:1-39.
16. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353-361.
17. Chen RH, Miettinen PJ, Maruoka EM, Choy L, Derynck R. A WD-domain protein that is associated with and phosphorylated by the type II TGF-beta receptor. Nature 1995;377:548-552.
18. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003;278:15461-15464.
19. Schalm SS, Blenis J. Identification of a conserved motif required for mTOR signaling. Curr Biol 2002;12:632-639.
20. Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 2003;13:797-806.
21. Choy L, Derynck R. The type II transforming growth factor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response. J Biol Chem 1998;273:31455-31462.
22. Rajasekhar VK, Holland EC. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene 2004;23:3248-3264.
23. Clemens MJ, Bommer UA. Translational control: The cancer connection. Int J Biochem Cell Biol 1999;31:1-23.
24. Naranda T, Kainuma M, MacMillan SE, Hershey JW. The 39-kilodalton subunit of eukaryotic translation initiation factor 3 is essential for the complex's integrity and for cell viability in Saccharomyces cerevisiae. Mol Cell Biol 1997;17:145-153.
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
26. Pandolfi PP. Aberrant mRNA translation in cancer pathogenesis: An old concept revisited comes finally of age. Oncogene 2004;23:3134-3137.
27. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005;16:797-803.
28. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004;4:335-348.
29. Moissoglu K, Sachdev S, Gelman IH. Enhanced v-Src-induced oncogenic transformation in the absence of focal adhesion kinase is mediated by phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 2005;330:673-684.
30. Brock R, Hamelers IH, Jovin TM. Comparison of fixation protocols for adherent cultured cells applied to a GFP fusion protein of the epidermal growth factor receptor. Cytometry 1999;35:353-362.